Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Vertex Pharmaceuticals, led by Indian American CEO Reshma Kewalramani, saw its shares tumble this month after disappointing results from its pain drug program. The company announced that its ...

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Shantanu Narayen, Reshma Kewalramani, Neal Mohan, Mukesh Ambani and Gautam Adani also make the Fortune 100 Most Powerful ...

Two Boston CEOs landed among the top 100, as did another familiar name in local business circles. The post Fortune’s list of ...

Jensen Huang, the CEO and cofounder of Nvidia, is at the top of the 2025 list. His business is now a major provider of ...

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named among Fortune’s 100 Most Powerful People in ...

Reshma Kewalramani, an Indian-origin CEO of Vertex Pharmaceuticals, made history as the first woman to lead a major US ...

Kewalramani, CEO of Vertex Pharmaceuticals, joins Fortune's 100 Most Powerful People in Business. Ranked 62nd, she is the 1st ...

Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.